Cite
HARVARD Citation
Peereboom, D. et al. (n.d.). 373OResults of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM). Annals of oncology. p. . [Online].